{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:05:18Z","timestamp":1760148318116,"version":"build-2065373602"},"reference-count":142,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite the development of anti-myeloma therapeutics, such as proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and autologous stem cell transplantation (ASCT), multiple myeloma remains incurable. A trial treatment combining four drugs\u2014daratumumab, carfilzomib, lenalidomide, and dexamethasone\u2014followed by ASCT frequently results in minimal residual disease (MRD) negativity and prevents progressive disease in patients with standard- and high-risk cytogenetics; however, it is insufficient to overcome the poor outcomes in patients with ultra-high-risk chromosomal aberration (UHRCA). In fact, MRD status in autografts can predict clinical outcomes after ASCT. Therefore, the current treatment strategy might be insufficient to overcome the negative impact of UHRCA in patients with MRD positivity after the four-drug induction therapy. High-risk myeloma cells lead to poor clinical outcomes not only by aggressive myeloma behavior but also via the generation of a poor bone marrow microenvironment. Meanwhile, the immune microenvironment effectively suppresses myeloma cells with a low frequency of high-risk cytogenetic abnormalities in early-stage myeloma compared to late-stage myeloma. Therefore, early intervention might be key to improving clinical outcomes in myeloma patients. The purpose of this review is to improve clinical outcomes in patients with UHRCA by considering MRD assessment results and improvement of the microenvironment.<\/jats:p>","DOI":"10.3390\/cancers15092418","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T02:06:11Z","timestamp":1682301971000},"page":"2418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Nishiwaki, K., and Yano, S. (2021). Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. Cancers, 13.","DOI":"10.3390\/cancers13194867"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Nishiwaki, K., and Yano, S. (2021). Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020215"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 Abnormalities in Multiple Myeloma: A Review of Translational, Clinical Research, and Therapeutic Strategies","volume":"14","author":"Bisht","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","article-title":"Comprehensive Genomic Analysis of Refractory Multiple Myeloma Reveals a Complex Mutational Landscape associated with Drug Resistance and Novel Therapeutic Vulnerabilities","volume":"107","author":"Giesen","year":"2022","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative Analysis of the Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/s41388-022-02227-8","article-title":"P53-NEIL1 Co-abnormalities Induce Genomic Instability and Promote Synthetic Lethality with Chk1 Inhibition in Multiple Myeloma Having Concomitant 17p13(Del) and 1q21(Gain)","volume":"41","author":"Teoh","year":"2022","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hanamura, I. (2021). Gain\/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020256"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and Overexpression of CKS1B at Chromosome Band 1q21 Is Associated with Reduced Levels of P27 Kip1 and an Aggressive Clinical Course in Multiple Myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple Myeloma Patients with CKS1B Gene Amplification Have a Shorter Progression-Free Survival Post-autologous Stem Cell Transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-Expression of CKS1B Activates Both MEK\/ERK and JAK\/STAT3 Signaling Pathways and Promotes Myeloma Cell Drug-Resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/geno.1994.1523","article-title":"Human and Mouse Chromosomal Mapping of the Myeloid Cell Leukemia-1 Gene: MCL1 Maps to Human Chromosome 1q21, a Region That Is Frequently Altered in Preneoplastic and Neoplastic Disease","volume":"23","author":"Craig","year":"1994","journal-title":"Genomics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gcc.2","article-title":"MCL1 Gene Co-expression Module Stratifies Multiple Myeloma and Predicts Response to Proteasome Inhibitor-Based Therapy","volume":"57","author":"Samo","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone Marrow Microenvironment\u2013Derived Signals Induce Mcl-1 Dependence in Multiple Myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ejh.13435","article-title":"Clinical Benefit of Ixazomib plus Lenalidomide-Dexamethasone in Myeloma Patients with Non-canonical NF-\u03baB Pathway Activation","volume":"105","author":"Dash","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma without Intention for Immediate Autologous Stem-Cell Transplantation (Endurance): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT Pathway Regulates CD38 on Myeloma Cells in the Bone Marrow Microenvironment: Therapeutic Implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in High-Risk Relapsed\/Refractory Multiple Myeloma Patients: Adverse Effect of Chromosome 1q21 Gain\/Amplification and GEP70 Status on Outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.imlet.2019.02.002","article-title":"Reprint of \u201cImmunomodulatory Effects of CD38-Targeting Antibodies\u201d","volume":"205","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.17925","article-title":"Identification of Patients at High Risk of Secondary Extramedullary Multiple Myeloma Development","volume":"196","author":"Stork","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41379-020-00669-7","article-title":"The Survival Impact of CKS1B Gains or Amplification Is Dependent on the Background Karyotype and TP53 Deletion Status in Patients with Myeloma","volume":"34","author":"Hao","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-Specific Microenvironmental Impact and Drug Response in Refractory Multiple Myeloma Revealed by Single-Cell Transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1Q Is Associated with Early Progression in Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.bbmt.2016.09.003","article-title":"Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation","volume":"22","author":"Bock","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","article-title":"Prognostic Significance of Cytogenetic Heterogeneity in Patients with Newly Diagnosed Multiple Myeloma","volume":"2","author":"Merz","year":"2018","journal-title":"Blood Adv."},{"key":"ref_31","first-page":"38","article-title":"Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial","volume":"136","author":"Ruggeri","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.12223","article-title":"Cytogenetics of Extramedullary Manifestations in Multiple Myeloma","volume":"161","author":"Billecke","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary Intracranial Localization of Multiple Myeloma and Treatment with Novel Agents: A Retrospective Survey of 50 Patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","article-title":"Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases","volume":"15","author":"Deng","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 Are Exclusively Associated with Del(17p) in Multiple Myeloma","volume":"95","author":"Eveillard","year":"2010","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal Selection and Double-Hit Events Involving Tumor Suppressor Genes Underlie Relapse in Myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"ref_37","first-page":"665","article-title":"Deregulation and Targeting of TP53 Pathway in Multiple Myeloma","volume":"8","author":"Escure","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Over-represented in High-Risk Disease Even in the Era of Novel Agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","article-title":"The Level of Deletion 17p and Bi-allelic Inactivation of TP53 Has a Significant Impact on Clinical Outcome in Multiple Myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ncb3380","article-title":"Proteasome Machinery Is Instrumental in a Common Gain-of-Function Program of the p53 Missense Mutants in Cancer","volume":"18","author":"Walerych","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1038\/bcj.2017.76","article-title":"Prevalence and Timing of TP53 Mutations in Del(17p) Myeloma and Effect on Survival","volume":"7","author":"Chin","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High Subclonal Fraction of 17p Deletion Is Associated with Poor Prognosis in Multiple Myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of Acquired Del(17p) in Multiple Myeloma","volume":"3","author":"Lakshman","year":"2019","journal-title":"Blood Adv."},{"key":"ref_45","first-page":"870","article-title":"The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma","volume":"15","author":"Lancman","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 Reactivates Mutant P53 by Covalent Binding to the Core Domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting P53 In Vivo: A First-in-Human Study with P53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem-Cell Transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kostopoulos, I.V., Eleutherakis-Papaiakovou, E., Rousakis, P., Ntanasis-Stathopoulos, I., Panteli, C., Orologas-Stavrou, N., Kanellias, N., Malandrakis, P., Liacos, C.I., and Papaioannou, N.E. (2021). Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 13.","DOI":"10.3390\/cancers13164047"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.transproceed.2018.02.131","article-title":"Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients after Autologous Peripheral Blood Stem Cell Transplantation in Long-Term Observation","volume":"50","author":"Snarski","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bmt.2008.318","article-title":"Contaminating Tumour Cells in Autologous PBSC Grafts Do Not Influence Survival or Relapse Following Transplant for Multiple Myeloma or B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"43","author":"Ho","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3324\/haematol.10535","article-title":"Relapse Risk after Autologous Transplantation in Patients with Newly Diagnosed Myeloma Is Not Related with Infused Tumor Cell Load and the Outcome Is Not Improved by CD34+ Cell Selection: Long Term Follow-Up of an EBMT Phase III Randomized Study","volume":"92","author":"Bourhis","year":"2007","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","article-title":"Randomized Trial of Filgrastim versus Chemotherapy and Filgrastim Mobilization of Hematopoietic Progenitor Cells for Rescue in Autologous Transplantation","volume":"98","author":"Narayanasami","year":"2001","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/bjh.18103","article-title":"Early Achievement of Measurable Residual Disease Negativity in the Treatment of Multiple Myeloma as Predictor of Outcome","volume":"197","author":"Baumelou","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2022-157960","article-title":"Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant","volume":"140","author":"Pasvolsky","year":"2022","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2022-160271","article-title":"Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma","volume":"140","author":"Nishimura","year":"2022","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD Assessment in Multiple Myeloma: Progress and Challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood Monitoring of Circulating Tumor Plasma Cells by Next Generation Flow in Multiple Myeloma after Therapy","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by Deep Sequencing from Circulating Tumor DNA Does Not Correlate with Results Obtained in the Bone Marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41409-018-0245-y","article-title":"Peripheral Flow-MRD Status at the Time of Autologous Stem Cell Collection Predicts Outcome in Multiple Myeloma","volume":"53","author":"Moor","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","article-title":"Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival after High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial","volume":"19","author":"Stewart","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00432-004-0635-y","article-title":"Myeloma Cell Contamination of Peripheral Blood Stem-Cell Grafts Can Predict the Outcome in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation","volume":"131","author":"Vogel","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-Based Induction\/Consolidation with or without Autologous Transplant (ASCT) Followed by Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) Maintenance: Efficacy in High-Risk Patients","volume":"39","author":"Gay","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbmt.2020.04.011","article-title":"Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma","volume":"26","author":"Bal","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41409-018-0170-0","article-title":"Combination Therapy with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Results in an Unprecedented Purity of the Stem Cell Graft in Newly Diagnosed Patients with Myeloma","volume":"53","author":"Tageja","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18 F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group Consensus Recommendations on Imaging in Monoclonal Plasma Cell Disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients with Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1182\/blood-2022-156730","article-title":"Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New Criteria for Response Assessment: Role of Minimal Residual Disease in Multiple Myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18 F-FDG\u2013PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive Role of Diffusion-Weighted Whole-Body MRI (DW-MRI) Imaging Response According to MY-RADS Criteria after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma and Combined Evaluation with MRD Assessment by Flow Cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A Personalized Mass Spectrometry\u2013Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of Detecting Serum Monoclonal Protein by MASS-Fix Following Stem Cell Transplantation in Multiple Myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single Cell Dissection of Plasma Cell Heterogeneity in Symptomatic and Asymptomatic Myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The Molecular Make up of Smoldering Myeloma Highlights the Evolutionary Pathways Leading to Multiple Myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"844604","DOI":"10.3389\/fgene.2022.844604","article-title":"Cellular Interaction Analysis Characterizing Immunosuppressive Microenvironment Functions in MM Tumorigenesis from Precursor Stages","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Papadimitriou, K., Tsakirakis, N., Malandrakis, P., Vitsos, P., Metousis, A., Orologas-Stavrou, N., Ntanasis-Stathopoulos, I., Kanellias, N., Eleutherakis-Papaiakovou, E., and Pothos, P. (2020). Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12113245"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal Residual Disease Monitoring and Immune Profiling in Multiple Myeloma in Elderly Patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2014.105866","article-title":"The Bone Marrow of Myeloma Patients Is Steadily Inhabited by a Normal-Sized Pool of Functional Regulatory T Cells Irrespective of the Disease Status","volume":"99","author":"Foglietta","year":"2014","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3389\/fimmu.2019.01596","article-title":"Mass Cytometry Discovers Two Discrete Subsets of CD39\u2212Treg Which Discriminate MGUS from Multiple Myeloma","volume":"10","author":"Kruzins","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","article-title":"Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma","volume":"25","author":"Bhutani","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal Flow Cytometry Identified \u201cMinimal Residual Disease\u201d (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"1","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering Multiple Myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","article-title":"European Myeloma Network Review and Consensus Statement on Smoldering Multiple Myeloma: How to Distinguish (and Manage) Dr. Jekyll and Mr Hyde","volume":"106","author":"Musto","year":"2021","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with Carfilzomib-Lenalidomide-Dexamethasone with Lenalidomide Extension in Patients with Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Followed by HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2021-148423","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Followed by HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"138","author":"Mateos","year":"2021","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2022-159606","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)","volume":"140","author":"Mateos","year":"2022","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone plus Autologous Transplantation or Carfilzomib plus Lenalidomide and Dexamethasone, Followed by Maintenance with Carfilzomib plus Lenalidomide or Lenalidomide Alone for Patients with Newly Diagnosed Multiple Myeloma (Forte): A Randomised, Open-Label, Phase 2 Trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142584","article-title":"Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final Results of a Phase 2 Trial of Extended Treatment (Tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","article-title":"Daratumumab Carfilzomib Lenalidomide and Dexamethasone as Induction Therapy in High-Risk, Transplant-Eligible Patients with Newly Diagnosed Myeloma: Results of the Phase 2 Study IFM 2018\u201304","volume":"40","author":"Touzeau","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma","volume":"28","author":"Guerrero","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/10428190410001663644","article-title":"Effect of DCEP Mobilizing Regimen in in Vivo Purging of PBSC Harvests in Multiple Myeloma","volume":"45","author":"Novella","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-141562","article-title":"Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma","volume":"136","author":"Atrash","year":"2020","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene Vicleucel (Ide-Cel; bb2121), a BCMA-Targeted CAR T-Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa Results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A Phase Ib\/II Study of JNJ-4528, a B-Cell Maturation Antigen (BCMA)-Directed CAR-T-Cell Therapy, in Relapsed\/Refractory Multiple Myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-Like Regimens in Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_112","first-page":"1318","article-title":"Plasma Pharmacokinetics of High-Dose Oral Melphalan in Patients Treated with Trialkylator Chemotherapy and Autologous Bone Marrow Reinfusion","volume":"49","author":"Choi","year":"1989","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00000421-199002000-00006","article-title":"Pharmacokinetics of Very High-Dose Oral Melphalan in Cancer Patients","volume":"13","author":"Boros","year":"1990","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-Dose Intravenous Melphalan: A Review","volume":"13","author":"Samuels","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus Lenalidomide versus Autologous Transplantation, Followed by Lenalidomide plus Prednisone versus Lenalidomide Maintenance, in Patients with Multiple Myeloma: A Randomised, Multicentre, Phase 3 Trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib\u2013Melphalan\u2013Prednisone, with or without Bortezomib\u2013Lenalidomide\u2013Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal Residual Disease Negativity Using Deep Sequencing Is a Major Prognostic Factor in Multiple Myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-Term Follow-Up of BMT CTN 0702 (STaMINA) of Postautologous Hematopoietic Cell Transplantation (AutoHCT) Strategies in the Upfront Treatment of Multiple Myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with Daratumumab or Observation Following Treatment with Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab and Autologous Stem-Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma (Cassiopeia): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide Maintenance versus Observation for Patients with Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-Thalidomide-Dexamethasone Is Superior to Thalidomide-Dexamethasone as Consolidation Therapy after Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2022-159540","article-title":"Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (PPCL): The UK Optimum\/Muknine Trial","volume":"140","author":"Kaiser","year":"2022","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D Is a Target for the Immunotherapy of Multiple Myeloma with Rationally Designed CAR T Cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G Protein-Coupled Receptor 5D in the Bone Marrow Is Associated with Poor Prognosis in Patients with Multiple Myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape\u2013Driven Relapse in Multiple Myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-Label, Phase 3 Trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 Humanized Monoclonal Antibody HuLuc63 Inhibits Myeloma Cell Adhesion and Induces Antibody-Dependent Cellular Cytotoxicity in the Bone Marrow Milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) Induces Proliferation and Autocrine Cytokine Expression on Human B Lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/eji.200424917","article-title":"Molecular and Functional Characterization of a CS1 (CRACC) Splice Variant Expressed in Human NK Cells That Does Not Contain Immunoreceptor Tyrosine-Based Switch Motifs","volume":"34","author":"Lee","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The Cytotoxicity Receptor CRACC (CS\u22121) Recruits EAT-2 and Activates the PI3K and Phospholipase C\u03b3 Signaling Pathways in Human NK Cells","volume":"175","author":"Tassi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41375-021-01172-x","article-title":"Selective Elimination of Immunosuppressive T Cells in Patients with Multiple Myeloma","volume":"35","author":"Awwad","year":"2021","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:21:28Z","timestamp":1760124088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":142,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15092418"],"URL":"https:\/\/doi.org\/10.3390\/cancers15092418","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,4,22]]}}}